NEW YORK (GenomeWeb) – Metamark Genetics said today that it has received Medicare coverage for ProMark, its proteomic test for prognosing early-stage prostate cancer.

Medicare Administrative Contractor Palmetto GBA issued a final local coverage decision for the test effective Oct. 10, 2016.

ProMark is a tool for identifying prostate cancer patients with likely non-aggressive forms of the disease that can be treated without surgery or radiation therapy. The test is intended for use in patients with biopsy Gleason Scores of 3+3 and 3+4.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Nov
15
Sponsored by
Twist Bioscience

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.